GBG Forschungs GmbH (German Breast Group)

Industry / private company


Location: Neu-Isenburg, Germany (DE) DE

ISNI: 0000000404572954

ROR: https://ror.org/03c8hnh70

Show on Map:

close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer (2014) Loibl S, Von Minckwitz G, Schneeweiss A, Paepke S, Lehmann A, Rezai M, Zahm DM, et al. Journal article Response and prognosis after neoadjuvant chemotherapy in 1,051 patients with infiltrating lobular breast carcinoma (2014) Loibl S, Volz C, Mau C, Blohmer JU, Costa SD, Eidtmann H, Fasching P, et al. Journal article Surgical outcome after neoadjuvant chemotherapy and bevacizumab: results from the GeparQuinto study (GBG 44) (2014) Gerber B, Von Minckwitz G, Eidtmann H, Rezai M, Fasching P, Tesch H, Eggemann H, et al. Journal article Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro) (2014) Von Minckwitz G, Rezai M, Fasching P, Huober J, Tesch H, Bauerfeind I, Hilfrich J, et al. Journal article Chemotherapy for 70-Year-old women with breast cancer in Germany: A survey by the German breast group (2013) Barinoff J, Traut A, Bauerschlag DO, Bischoff J, Herr D, Luebbe K, Lueck HJ, et al. Journal article Everolimus as treatment for breast cancer patients with bone metastases only: Results of the phase II RADAR study (2013) Maass N, Harbeck N, Mundhenke C, Lerchenmueller C, Barinoff J, Lueck HJ, Ettl J, et al. Journal article Neutrophil Gelatinase-Associated Lipocalin (NGAL) Predicts Response to Neoadjuvant Chemotherapy and Clinical Outcome in Primary Human Breast Cancer (2012) Wenners AS, Mehta K, Loibl S, Park H, Mueller B, Arnold N, Hamann S, et al. Journal article Trastuzumab beyond progression: Overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer (2011) Von Minckwitz G, Schweller K, Schmidt M, Barinoff J, Mundhenke C, Cufer T, Maartense E, et al. Journal article Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial (2010) Witzel I, Loibl S, Von Minckwitz G, Mundhenke C, Huober J, Hanusch C, Henschen S, et al. Journal article
‹ 1 ... 14 15 16 ›